Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR119 | Q8TDV5 | 4/20 | 0.43 |
| ▸ | KDM1A | O60341 | 6/20 | 0.41 |
| ▸ | EGLN2 | Q96KS0 | 5/20 | 0.39 |
| ▸ | DCK | P27707 | 1/20 | 0.35 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.34 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.34 |
| ▸ | NSD2 | O96028 | 1/20 | 0.34 |
| ▸ | PDE4A | P27815 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL389779 | 0.83 | GPR119 (0.62) | GPR119 | |
| SCHEMBL388537 | 0.81 | GPR119 (0.40) | GPR119KDM1AEGLN2DCK | |
| SCHEMBL386361 | 0.80 | GPR119 (0.54) | GPR119 | |
| SCHEMBL12904825 | 0.79 | KDM1A (0.41) | GPR119KDM1AEGLN2 | |
| SCHEMBL12835774 | 0.73 | GPR119 (0.43) | GPR119KDM1ADCKCHRM3SLC6A2 | |
| SCHEMBL6066219 | 0.73 | GPR119 (0.48) | GPR119KDM1ADCKSLC6A2 | |
| SCHEMBL389918 | 0.72 | GPR119 (0.61) | GPR119 | |
| SCHEMBL5048756 | 0.70 | GPR119 (0.67) | GPR119 | |
| SCHEMBL389723 | 0.68 | GPR119 (0.40) | GPR119KDM1ADCK | |
| SCHEMBL1071729 | 0.68 | GPR119 (0.53) | GPR119 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2004157-A2 | USE OF GPR119 RECEPTOR AGONISTS FOR INCREASING BONE MASS AND FOR TREATING OSTEOPOROSIS, AS WELL AS COMBINATION THERAPY RELATING THERETO | Arena Pharmaceuticals, Inc. (US) | 2008-12-24 | — | — | EP | disclosed |
| WO-2007120702-A2 | USE OF GPR119 RECEPTOR AGONISTS FOR INCREASING BONE MASS AND FOR TREATING OSTEOPOROSIS, AND COMBINATION THERAPY RELATING THERETO | ARENA PHARMACEUTICALS, INC. (US) | 2007-10-25 | — | — | WO | disclosed |